Genetics of ischaemic stroke

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 12, 2013, Pages 1302-1308

  Sharma, Pankaj ^a   Yadav, Sunaina ^a   Meschia, James F ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; CENTRAL NERVOUS SYSTEM AGENTS; DICHLOROACETIC ACID; HOMOCYSTEINE; IDEBENONE; LACTIC ACID; NOTCH3 RECEPTOR; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; PYRUVIC ACID; RECOMBINANT ALPHA GALACTOSE; STEROID; UBIDECARENONE; UNCLASSIFIED DRUG; VITAMIN; VITAMIN B COMPLEX;

ALOPECIA; ALPHA GAL GENE; AMINO ACID BLOOD LEVEL; APATHY; BRAIN ATHEROSCLEROSIS; BRAIN ISCHEMIA; CADASIL; CARDIOEMBOLIC STROKE; CELIAC DISEASE; CEREBRAL AUTOSOMAL RECESSIVE ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY; CONFORMATIONAL TRANSITION; COPY NUMBER VARIATION; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; EMOTIONAL DISORDER; ENZYME REPLACEMENT; EUPHORIA; FABRY DISEASE; GASTROINTESTINAL SYMPTOM; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETIC VARIABILITY; GENETICS; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HERITABILITY; HISTOPATHOLOGY; HOMOCYSTINURIA; HTRA1 GENE; HUMAN; HYPERTENSION; INTERVERTEBRAL DISK HERNIA; LACTATE BLOOD LEVEL; LACUNAR STROKE; LOW BACK PAIN; MELAS SYNDROME; MENDELIAN RANDOMIZATION ANALYSIS; MIGRAINE; MIGRAINE WITH AURA; MISSENSE MUTATION; MOLECULAR DIAGNOSIS; MONOGENIC DISORDER; MOOD DISORDER; MTHFR GENE; MUTATIONAL ANALYSIS; NEUROTOXICITY; NONHUMAN; NOTCH3 GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PITX2 GENE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK FACTOR; SEIZURE; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL CORD LESION; SPORADIC ISCHEMIC STROKE; TRANSIENT ISCHEMIC ATTACK; VITAMIN SUPPLEMENTATION; WERNICKE ENCEPHALOPATHY; WHITE MATTER LESION; ZFHX3 GENE;

EID: 84888040015     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304834     Document Type: Review

References (118)

1. Muqtadar H, Testai FD. Single gene disorders associated with stroke: a review and update on treatment options. Curr Treat Options Cardiovasc Med 2012;14:288-97.
2. Della-Morte D, Guadagni F, Palmirotta R, et al. Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments. Pharmacogenomics 2012;13:595-613.
3. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-10.
4. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
5. Yadav S, Bentley P, Srivastava P, et al. J Stroke Cerebrovasc Dis 2013;22:28-31.
6. Razvi SS, Davidson R, Bone I, et al. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry 2005;76:739-41.
7. Chabriat H, Pappata S, Ostergaard L, et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke 2000;31:1904-12.
8. O'Sullivan M, Jarosz JM, Martin RJ, et al. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology 2001;56:628-34.
9. Bentley P, Wang T, Malik O, et al. CADASIL with cord involvement associated with a novel and atypical NOTCH3 mutation. J Neurol Neurosurg Psychiatry 2011;82:855-60.
10. Sharma P, Wang T, Brown MJ, et al. Fits and strokes. Lancet 2001;358:120.
11. Herve D, Chabriat H. Cadasil. J Geriatr Psychiatry Neurol 2010;23:269-76.
12. Ayata C. CADASIL: experimental insights from animal models. Stroke 2010;41:S129-34.
13. Adib-Samii P, Brice G, Martin RJ, et al. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke 2010;41:630-4.
14. Mizuno T. [Diagnosis, pathomechanism and treatment of CADASIL]. Rinsho Shinkeigaku 2012;52:303-13.
15. Schmidt H, Zeginigg M, Wiltgen M, et al. Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease. Brain 2011;134:3384-97.
16. Monet-Lepretre M, Bardot B, Lemaire B, et al. Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain. Brain 2009;132:1601-12.
17. Opherk C, Peters N, Herzog J, et al. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain 2004;127:2533-9.
18. del Rio-Espinola A, Mendioroz M, Domingues-Montanari S, et al. CADASIL management or what to do when there is little one can do. Expert Rev Neurother 2009;9:197-210.
19. Donnini I, Nannucci S, Valenti R, et al. Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience. J Headache Pain 2012;13:299-302.
20. Fukutake T, Hirayama K. Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur Neurol 1995;35:69-79.
21. Hara K, Shiga A, Fukutake T, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 2009;360:1729-39.
22. Fukutake T. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL): from discovery to gene identification. J Stroke Cerebrovasc Dis 2011;20:85-93.
23. Arima K, Yanagawa S, Ito N, et al. Cerebral arterial pathology of CADASIL and CARASIL (Maeda syndrome). Neuropathology 2003;23:327-34.
24. Toyooka K. Fabry disease. Curr Opin Neurol 2011;24:463-8.
25. Rolfs A, Bottcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366:1794-6.
26. Sims K, Politei J, Banikazemi M, et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009;40:788-94.
27. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40.
28. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-28.
29. Tanislav C, Kaps M, Rolfs A, et al. Frequency of Fabry disease in patients with small-fibre neuropathy of unknown aetiology: a pilot study. Eur J Neurol 2011;18:631-6.
30. Mitsias P, Levine SR. Cerebrovascular complications of Fabry 's disease. Ann Neurol 1996;40:8-17.
31. Fellgiebel A, Keller I, Marin D, et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 2009;72:63-8.
32. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009;374:1986-96.
33. Lidove O, West ML, Pintos-Morell G, et al. Effects of enzyme replacement therapy in Fabry disease - a comprehensive review of the medical literature. Genet Med 2010;12:668-79.
34. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011;42:227-76.
35. Germain DP. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy. Clin Ther 2007;29(Suppl A):S17-18.
36. Goto Y, Horai S, Matsuoka T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 1992;42:545-50.
37. Manwaring N, Jones MM, Wang JJ, et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion 2007;7:230-3.
38. Testai FD, Gorelick PB. Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Arch Neurol 2010;67:19-24.
39. Yoneda M, Maeda M, Kimura H, et al. Vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging. Neurology 1999;53:2182-4.
40. Ito H, Mori K, Harada M, et al. Serial brain imaging analysis of stroke-like episodes in MELAS. Brain Dev 2008;30:483-8.
41. Yamada K, Toribe Y, Yanagihara K, et al. Diagnostic accuracy of blood and CSF lactate in identifying children with mitochondrial diseases affecting the central nervous system. Brain Dev 2012;34:92-7.
42. Santa KM. Treatment options for mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. Pharmacotherapy 2010;30:1179-96.
43. Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35:235-42.
44. Napolitano A, Salvetti S, Vista M, et al. Long-term treatment with idebenone and ribofl avin in a patient with MELAS. Neurol Sci 2000;21:S981-2.
45. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006;66:324-30.
46. Koga Y, Povalko N, Nishioka J, et al. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci 2010;1201:104-10.
47. Switzer JA, Hess DC, Nichols FT, et al. Pathophysiology and treatment of stroke in sickle-cell disease: present and future. Lancet Neurol 2006;5:501-12.
48. Kelly PJ, Furie KL, Kistler JP, et al. Stroke in young patients with hyperhomocysteinemia due to cystathionine beta-synthase deficiency. Neurology 2003;60:275-9.
49. Schmidt R, Enzinger C, Ropele S, et al. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003;361:2046-8.
50. Rost N. White Matter Disease. In: Sharma P, Meschia JF, eds. Stroke genetics. London: Springer, 2013:171-88.
51. Kuller LH, Longstreth WT Jr, Arnold AM, et al. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke 2004;35:1821-5.
52. de Groot JC, de Leeuw FE, Oudkerk M, et al. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology 2001;56:1539-45.
53. Carmelli D, DeCarli C, Swan GE, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998;29:1177-81.
54. Turner ST, Fornage M, Jack CR Jr, et al. Genomic susceptibility loci for brain atrophy in hypertensive sibships from the GENOA study. Hypertension 2005;45:793-8.
55. Fornage M, Debette S, Bis JC, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011;69:928-39.
56. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112-23.
57. Jeffs B, Clark JS, Anderson NH, et al. Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. Nat Genet 1997;16:364-7.
58. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004;35:212-27.
59. Jousilahti P, Rastenyte D, Tuomilehto J, et al. Parental history of cardiovascular disease and risk of stroke. A prospective follow-up of 14371 middle-aged men and women in Finland. Stroke 1997;28:1361-6.
60. Liao D, Myers R, Hunt S, et al. Familial history of stroke and stroke risk. The Family Heart Study. Stroke 1997;28:1908-12.
61. Bak S, Gaist D, Sindrup SH, et al. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke 2002;33:769-74.
62. Brass LM, Isaacsohn JL, Merikangas KR, et al. A study of twins and stroke. Stroke 1992;23:221-3.
63. Jood K, Ladenvall P, Tjarnlund-Wolf A, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke 2005;36:2077-81.
64. Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke 2004;35:819-24.
65. Flossmann E, Rothwell PM. Family history of stroke does not predict risk of stroke after transient ischemic attack. Stroke 2006;37:544-6.
66. Flossmann E, Rothwell PM. Family history of stroke in patients with transient ischemic attack in relation to hypertension and other intermediate phenotypes. Stroke 2005;36:830-5.
67. Bevan S, Traylor M, Adib-Samii P, et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke 2012;43:3161-7.
68. Bentley P, Peck G, Smeeth L, et al. Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants. PLoS ONE 2010;5:e9136.
69. Casas JP, Bautista LE, Smeeth L, et al. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-32.
70. Cheng YC, Anderson CD, Bione S, et al. Are myocardial infarction-associated single-nucleotide polymorphisms associated with ischemic stroke? Stroke 2012;43:980-6.
71. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994;1:333-9.
72. Kannel WB, Wolf PA. Peripheral and cerebral atherothrombosis and cardiovascular events in different vascular territories: insights from the Framingham Study. Curr Atheroscler Rep 2006;8:317-23.
73. Casas JP, Hingorani AD, Bautista LE, et al. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004;61:1652-61.
74. Ariyaratnam R, Casas JP, Whittaker J, et al. Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals. PloS Med 2007;4:e131.
75. Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009;41:666-76.
76. Ehret GB, Munroe PB, Rice KM, et al. International Consortium for Blood Pressure Genome-Wide Association S. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478:103-9.
77. Biffi A, Anderson CD, Jagiella JM, et al. APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol 2011;10:702-9.
78. Ebrahim S, Smith G Davey. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet 2008;123:15-33.
79. Casas JP, Bautista LE, Smeeth L, et al. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-32.
80. Zhou YH, Tang JY, Wu MJ, et al. Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. PLoS ONE 2011;6:e25142.
81. Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011;378:584-94.
82. Clarke R, Bennett DA, Parish S, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PloS Med 2012;9:e1001177.
83. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol 2011;40:755-64.
84. Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet 2008;17:R116-21.
85. Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum Mol Genet 2008;17:R109-15.
86. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003;35:131-8.
87. Rosand J, Bayley N, Rost N, et al. Many hypotheses but no replication for the association between PDE4D and stroke. Nat Genet 2006;38:1091-2; author reply 1092-1093.
88. Bevan S, Porteous L, Sitzer M, et al. Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis. Stroke 2005;36:949-53.
89. Bevan SDM, Gschwendtner A, Kuhlenbäumer G, et al. Variation in the PDE4D Gene and Ischemic Stroke Risk. A Systematic Review and Metaanalysis on 5200 Cases and 6600 Controls. Stroke 2008;39:1966-71.
90. Matsushita T, Kubo M, Yonemoto K, et al. Lack of association between variations of PDE4D and ischemic stroke in the Japanese population. Stroke 2009;40:1245-51.
91. Holliday EG, Maguire JM, Evans TJ, et al. Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet 2012;44:1147-51.
92. Worrall BB, Mychaleckyj JC. PDE4D and stroke: a real advance or a case of the Emperor's new clothes? Stroke 2006;37:1955-7.
93. Bellenguez C, Bevan S, Gschwendtner A, et al.; International Stroke Genetics C, Wellcome Trust Case Control C. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet 2012;44:328-33.
94. Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fi brillation and ischemic stroke. Nat Genet 2009;41:876-8.
95. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:353-7.
96. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identi fies six new susceptibility loci for atrial fibrillation. Nat Genet 2012;44:670-5.
97. Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 2012;11:951-62.
98. Lao O, Lu TT, Nothnagel M, et al. Correlation between genetic and geographic structure in Europe. Curr Biol 2008;18:1241-8.
99. Schrijvers EM, Schurmann B, Koudstaal PJ, et al. Genome-wide association study of vascular dementia. Stroke 2012;43:315-19.
100. Verhaaren BF, de Boer R, Vernooij MW, et al. Replication study of chr17q25 with cerebral white matter lesion volume. Stroke 2011;42:3297-9.
101. Kubo M, Hata J, Ninomiya T, et al. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat Genet 2007;39:212-17.
102. Yamada Y, Fuku N, Tanaka M, et al. Identification of CELSR1 as a susceptibility gene for ischemic stroke in Japanese individuals by a genome-wide association study. Atherosclerosis 2009;207:144-9.
103. Hata J, Matsuda K, Ninomiya T, et al. Functional SNP in an Sp1-binding site of AGTRL1 gene is associated with susceptibility to brain infarction. Hum Mol Genet 2007;16:630-9.
104. Matarin M, Brown WM, Singleton A, et al. Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke 2008;39:1586-9.
105. Bilguvar K, Yasuno K, Niemela M, et al. Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat Genet 2008;40:1472-7.
106. Ikram MA, Seshadri S, Bis JC, et al. Genomewide association studies of stroke. N Engl J Med 2009;360:1718-28.
107. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233-9.
108. Debette S, Bis JC, Fornage M, et al. Genome-wide association studies of MRI-defined brain infarcts: meta-analysis from the CHARGE Consortium. Stroke 2010;41:210-17.
109. International Stroke Genetics C, Wellcome Trust Case-Control C. Failure to validate association between 12p13 variants and ischemic stroke. N Engl J Med 2010;362:1547-50.
110. Anderson CD, Biffi A, Rahman R, et al. Common mitochondrial sequence variants in ischemic stroke. Ann Neurol 2011;69:471-80.
111. DeStefano AL, Atwood LD, Massaro JM, et al. Genome-wide scan for white matter hyperintensity: the Framingham Heart Study. Stroke 2006;37:77-81.
112. Bis JC, Kavousi M, Franceschini N, et al. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet 2011;43:940-7.
113. Cotlarciuc, I, Khan, MA, Maheshwari, A, et al. Bio-repository of DNA in stroke: a study protocol of three ancestral populations. J R Soc Med Cardiovasc Dis 2012;1:10.
114. Yadav S, Schanz R, Maheshwari A, et al. Bio-Repository of DNA in stroke (BRAINS): a study protocol. BMC Med Genet 2011;12:34.
115. Cole JW, Stine OC, Liu X, et al. Rare variants in ischemic stroke: an exome pilot study. PLoS ONE 2012;7:e35591.
116. Matarin M, Simon-Sanchez J, Fung HC, et al. Structural genomic variation in ischemic stroke. Neurogenetics 2008;9:101-8.
117. Tiszlavicz Z, Somogyvari F, Szolnoki Z, et al. Genetic polymorphisms of human beta-defensins in patients with ischemic stroke. Acta Neurol Scand 2012;126:109-15.
118. Norskov MS, Frikke-Schmidt R, Loft S, et al. Copy number variation in glutathione S-transferases M1 and T1 and ischemic vascular disease: four studies and meta-analyses. Circ Cardiovasc Genet 2011;4:418-28.